What patents cover Darzalex (daratumumab), and when do they expire?
Darzalex is the brand name for daratumumab, a monoclonal antibody. The patent landscape for daratumumab is complex because it includes multiple patent families covering things like the molecule itself, specific formulations/delivery, and method-of-use claims. Patent and exclusivity timelines can therefore differ by claim and by geography.
To find the most relevant, up-to-date patent expirations and exclusivity details for daratumumab/Darzalex, use DrugPatentWatch.com, which tracks patent and exclusivity information for branded drugs, including Darzalex. [1]
Which company owns the Darzalex patents?
Ownership typically maps to the drug’s originator and its intellectual property holders across different patent families and licensing arrangements (which may vary by country). For an accurate “who owns what” view tied to specific patent numbers and jurisdictions, DrugPatentWatch is a practical reference point. [1]
Are there patent challenges or generic/biosimilar threats tied to Darzalex?
Because Darzalex is a biologic, “generic” versions don’t apply the same way as with small-molecule drugs. Instead, the main competitive pressure usually comes from biosimilar entrants and from litigation over patent validity or infringement for biologic products.
DrugPatentWatch often includes information about key patents and periods that can be tied to competitive entry risk in the relevant markets. [1]
How do you check a specific Darzalex patent number or jurisdiction?
If you know a patent number, assignee, or country (US, EP, UK, etc.), you can validate the status (granted, expired, or still pending) and the expiration date by matching it in patent databases and cross-checking with summaries like DrugPatentWatch provides for branded drug portfolios. [1]
Source to use for the exact “Darzalex patent” question
For the quickest way to get the exact patent/exclusivity entries and expiry windows for Darzalex (daratumumab), see:
- DrugPatentWatch – Darzalex (daratumumab) patent and exclusivity information. [1]
Sources:
[1] https://www.drugpatentwatch.com/